<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02628795</url>
  </required_header>
  <id_info>
    <org_study_id>R01HD084124</org_study_id>
    <secondary_id>R01HD084124</secondary_id>
    <nct_id>NCT02628795</nct_id>
  </id_info>
  <brief_title>Overcoming TWEAK Signaling to Restore Muscle and Mobility After Joint Replacement</brief_title>
  <acronym>TWEAK</acronym>
  <official_title>Overcoming TWEAK Signaling to Restore Muscle and Mobility After Joint Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-blind, randomized, controlled trial is designed to test the effect of an
      intensive, 16 week exercise rehabilitation program (progressive resistance training +
      functional mobility training) vs. usual care on restoration of muscle mass and mobility after
      total hip (THA) or knee (TKA) arthroplasty in men and women with end-stage osteoarthritis.
      The molecular basis underlying the trial is the presence of significant muscle inflammation
      susceptibility in many of these individuals, and the expectation that the more intensive
      intervention will overcome this inflammatory burden to facilitate recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While elective total hip (THA) and knee (TKA) arthroplasty relieve pain and improve mobility
      function for thousands with end-stage osteoarthritis (OA), up to 35% endure persistent muscle
      atrophy and mobility limitations for several years that impact life quality, increase
      morbidity, and burden the healthcare system. Given that THA/TKA volumes are increasing
      exponentially with &gt;1.1 million in the US annually, refractory mobility impairment is a major
      public health problem. Together, the available data raise two important knowledge gaps in
      THA/TKA rehabilitation: (i) poorly understood factors that limit responsiveness of a large
      number of patients to current usual care; and (ii) the absence of rehabilitation programs
      proven to overcome these limitations. The proposed project is designed to fill these gaps.
      The investigators' fundamental tenet is that restoration of mobility function following
      THA/TKA requires: (i) regeneration of surgically damaged muscle; and (ii) regrowth of muscles
      that have atrophied over years of OA and limited usage. The investigators suggest a major
      cause of muscle regeneration impairment in some individuals is what the investigators
      identified as muscle inflammation susceptibility (MuIS) - hyperactive inflammatory signaling
      in muscle of MuIS(+) individuals despite no systemic inflammation - which also manifests in
      isolated primary satellite cells and inhibits myogenesis in vitro, indicative of a true
      cellular phenotype beyond the niche. The investigators' preliminary findings in THA/TKA
      patients strongly suggest the tumor necrosis factor-like weak inducer of apoptosis (TWEAK)
      signaling pathway may be central to MuIS and impaired THA/TKA recovery, as high perioperative
      muscle TWEAK signaling in the ipsilateral thigh was the most sensitive indicator of impaired
      muscle protein synthesis and failed strength recovery after 8 wk of usual care. Progressive
      resistance exercise training (PRT) is a putative anabolic intervention that the investigators
      find consistently increases muscle mass to meet healthy standards in atrophied and
      mobility-impaired adults, by activating muscle protein synthesis and the myogenic activity of
      muscle satellite cells. Together, these findings raise the central hypothesis that PRT plus
      adjunctive functional mobility training (PRT+FM) after THA/TKA will more effectively restore
      muscle mass and mobility function to healthy standards than usual care and, because MuIS(+)
      are predicted to suffer failed muscle recovery and persistent dismobility under usual care,
      the impact of PRT+FM will be greatest in MuIS(+). The investigators will thoroughly test this
      hypothesis in a randomized controlled trial of 88 THA/TKA patients with the following aims.
      Aim 1: To determine the effects of 16 wk of PRT+FM vs. usual care after elective THA/TKA on
      muscle mass, performance, and mobility function. Aim 2: To determine whether MuIS status
      modifies the effects of PRT+FM or usual care after THA/TKA. Cellular and molecular mechanisms
      of muscle mass regulation will be studied in detail. Aim 3. To determine the long-term impact
      of 16 wk PRT+FM by re-assessing outcomes at 6 mo and 1 y. The investigators fully expect the
      novel findings to lead a paradigm shift in THA/TKA rehabilitation that will have a profound
      impact on a growing segment of the population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in unilateral (surgical) thigh muscle mass (unit of measure = grams)</measure>
    <time_frame>Pre-surgery to 16 weeks post-surgery</time_frame>
    <description>Primary muscle mass outcome of Aim 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in unilateral (surgical) knee extension power (unit of measure = watts)</measure>
    <time_frame>Pre-surgery to 16 weeks post-surgery</time_frame>
    <description>Primary functional outcome of Aim 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in short physical performance battery (SPPB) (unit of measure = score)</measure>
    <time_frame>From 16 weeks post-surgery to 26 and 52 weeks post-surgery</time_frame>
    <description>Primary outcome of Aim 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle inflammation susceptibility (MuIS) status (unit of measure = relative value)</measure>
    <time_frame>At the time of surgery</time_frame>
    <description>Primary outcome of Aim 2: Muscle inflammation susceptibility (MuIS) defined by TWEAK receptor gene expression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle fiber size (unit of measure = micrometers squared)</measure>
    <time_frame>From the time of surgery to 16 weeks post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in unilateral (surgical) knee extension isometric strength (unit of measure = Newton-meters)</measure>
    <time_frame>Pre-surgery to 16 weeks post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum 10-meter gait speed (unit of measure = meters per second)</measure>
    <time_frame>Pre-surgery to 16 weeks post-surgery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in free-living physical activity (unit of measure = steps per day)</measure>
    <time_frame>Pre-surgery to 8, 16, 26, and 52 weeks post-surgery</time_frame>
    <description>Via wearable technology (i.e. step counter)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in self-reported health status (unit of measure = score)</measure>
    <time_frame>Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery</time_frame>
    <description>Via Short Form-36v2 Health Survey (SF-36v2)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in cellular and molecular markers (unit of measure = arbitrary units)</measure>
    <time_frame>From the time of surgery to 16 weeks post-surgery</time_frame>
    <description>Experiments using muscle tissue and primary muscle satellite cells collected from surgical and contralateral limbs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fatigue (unit of measure = score)</measure>
    <time_frame>Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery</time_frame>
    <description>Via Patient Reported Outcomes Measurement Information System (PROMIS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in pain (unit of measure = score)</measure>
    <time_frame>Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery</time_frame>
    <description>Via Patient Reported Outcomes Measurement Information System (PROMIS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in depression (unit of measure = score)</measure>
    <time_frame>Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery</time_frame>
    <description>Beck Depression Inventory (BDI II)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fatigue severity (unit of measure = score)</measure>
    <time_frame>Pre-surgery to 1, 8, 16, 26, and 52 weeks post-surgery</time_frame>
    <description>Fatigue Severity Scale (FSS)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>PRT + FM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progressive resistance training + functional mobility training 3 d/wk x 16 wk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Post-surgical usual care including physical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PRT + FM</intervention_name>
    <description>Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.</description>
    <arm_group_label>PRT + FM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Post-surgical usual care activities including any prescribed physical therapy</description>
    <arm_group_label>PRT + FM</arm_group_label>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages 40 and 80 y.

               -  Scheduled to undergo elective total hip or knee replacement specifically for the
                  surgical indication of end-stage osteoarthritis.

               -  First-time hip or knee replacement.

               -  Capable of providing informed consent (cognitively intact if consenting to
                  surgery).

        Exclusion Criteria:

          -  Any surgical indication other than first-time total joint replacement specifically for
             end-stage osteoarthritis.

               -  Bilateral knee/ hip replacement

               -  History of alcoholism or liver disease.

               -  Any history of hypo- or hyper-coagulation disorders including subjects taking
                  Coumadin.

               -  Any individual with end-stage disease and/or a life expectancy less than one
                  year.

               -  Pregnancy.

               -  Lactating Women.

               -  Neurological, musculoskeletal, or other disorder that would preclude them from
                  completing the exercise training intervention and all performance tests.

               -  Uncontrolled hypertension, unstable or exercise-induced angina pectoris or
                  myocardial ischemia, congestive heart failure.

               -  Uncontrolled diabetes mellitus.

               -  Any other condition or events considered exclusionary by the PIs and/or physician
                  Co-Is.

               -  Lidocaine allergy (1% lidocaine is the local anesthetic used during the muscle
                  biopsy procedure).

               -  Phenylketonuria (phenylalanine tracer for metabolic studies).

               -  Currently receiving androgen (e.g., testosterone) or anabolic (e.g., growth
                  hormone (GH), insulin-like growth factor-I (IGF-I)) therapy.

               -  Body mass index â‰¥ 35.

               -  History of lower body progressive resistance training within the past year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcas M Bamman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S Louis Bridges, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Layne Peacock, NP</last_name>
    <phone>205-934-6231</phone>
    <email>lpeacoc1@uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Selena Luckett-Smith, RN</last_name>
    <phone>205-934-7427</phone>
    <email>sluckett@uab.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UAB Center for Exercise Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Layne Peacock, NP</last_name>
      <phone>205-934-6231</phone>
      <email>lpeacoc1@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Steven C Tuggle, MA</last_name>
      <phone>205-934-6231</phone>
      <email>tugg12@uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marcas M Bamman, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>S Louis Bridges, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Herrick Siegel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jasvinder Singh, MBBS, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inmaculada Aban, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel T Windham, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Marcas M. Bamman, PhD</investigator_full_name>
    <investigator_title>Professor and Director, UAB Center for Exercise Medicine</investigator_title>
  </responsible_party>
  <keyword>total hip arthroplasty</keyword>
  <keyword>total knee arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data might be provided on written request in aggregate form.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

